<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520088</url>
  </required_header>
  <id_info>
    <org_study_id>TAU-RECTALNERV-PRESERV-2018</org_study_id>
    <nct_id>NCT03520088</nct_id>
  </id_info>
  <brief_title>PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS</brief_title>
  <official_title>PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Paula Planelles-Soler</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laura Mora-Lopez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Naim Hannaoui</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sheila Serra-Pla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arturo Dominguez-Garcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jesus Muñoz-Rodriguez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Joan Prats-Lopez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Salvador Navarro-Soto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xavier Serra-Aracil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: The &quot;Total Mesorectal Excision&quot; (TME) is the standard surgical technique for the
      treatment of rectal cancer. Up to 50% of sexual dysfunction is described after TME and up to
      30% of urinary dysfunction. The main objective of the study is to compare pre- and post-TME
      sexual dysfunction according to the approach of the inferior mesenteric vessels, directly on
      the IMA or from the inferior mesenteric vein (IMV) to the IMA.

      Methods: Multicenter, prospective, controlled and randomized study of patients with rectal
      adenocarcinoma with neoadjuvant chemoradiotherapy, who will be randomized into two groups
      depending on the approach of the inferior mesenteric vessels. The main variable is pre and
      postoperative sexual dysfunction. The sample to be included will be 90 patients, 45 per
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: The &quot;Total Mesorectal Excision&quot; (TME) is the standard surgical technique for the
      treatment of rectal cancer. Up to 50% of sexual dysfunction is described after TME and up to
      30% of urinary dysfunction. Although there are other factors, the main cause of postoperative
      genitourinary dysfunction is intraoperative injury of the autonomic pelvic nerves. One of the
      regions with more risk is the Inferior Mesenteric Artery (IMA). The main objective of the
      study is to compare pre- and post-TME sexual dysfunction according to the approach of the
      inferior mesenteric vessels, directly on the IMA or from the inferior mesenteric vein (IMV)
      to the IMA.

      Methods: Multicenter, prospective, controlled and randomized study of patients with rectal
      adenocarcinoma with neoadjuvant chemoradiotherapy, who will be randomized into two groups
      depending on the approach of the inferior mesenteric vessels. The main variable is pre and
      postoperative sexual dysfunction. The secondary variables are visualization and preservation
      of the pelvic autonomic nerves, pre- and postoperative urinary dysfunction, pre and
      postoperative quality of life. The sample to be included will be 90 patients, 45 per group.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The analysis of the results will be blind for the investigator</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in sexual dysfunction pre- and post-Total Mesorectal Excision</measure>
    <time_frame>1 week before surgery and 12 months post-surgery</time_frame>
    <description>Sexual dysfunction pre- and post-Total Mesorectal Excision by sexual dysfunction scale IIEF-5</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Inferior mesenteric Vein dissection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To improve and preserve the rectal nerve in the total mesorectal excision, its starts the dissection from the inferior mesenteric vein to the inferior mesenteric artery and through the pelvis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inferior mesenteric Artery dissection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>As standard, the dissection starts straight in the inferior mesenteric artery and through the pelvis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Inferior mesenteric Vein dissection</intervention_name>
    <description>Dissection of the Inferior mesenteric Vein first, and go down to the Artery during the total mesorectal excision</description>
    <arm_group_label>Inferior mesenteric Vein dissection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Inferior mesenteric Artery dissection</intervention_name>
    <description>Dissection of the Inferior mesenteric Artery directly in the total mesorectal excision</description>
    <arm_group_label>Inferior mesenteric Artery dissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males;

          -  Age greater (or equal) to 18 years

          -  Diagnosed of rectal adenocarcinoma at ≤ 15 cm from the anal margin (by rigid
             rectoscopy)

          -  Candidate for neoadjuvant (chemoradiotherapy).

          -  Scheduled laparoscopic radical TME surgery carried out by colorectal surgeons;

          -  ASA I, II or III;

          -  Informed consent present.

        Exclusion Criteria:

          -  women

          -  Under 18 years old;

          -  Not Candidate for neoadjuvant (chemoradiotherapy);

          -  Emergency surgery;

          -  Recurrent neoplasms

          -  cT4

          -  Patient with a history of infra-abdominal, or pelvic surgery of the prostate, or
             radiotherapy prior to the current process;

          -  Patients with severe sexual dysfunction and neurological alterations before surgery

          -  Patients with neurogenic bladder before surgery.

          -  Not to sign the informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male. The main objective of the study is asses the sexual dysfunction in male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Pallisera-Lloveras, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corporacio Parc Tauli. Parc Tauli University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Pallisera-Lloveras, MD, PhD</last_name>
    <phone>34-93-723-1010</phone>
    <phone_ext>21490</phone_ext>
    <email>apallill@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Parc Tauli University Hospital</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Pallisera-Lloveras, MD,PhD</last_name>
      <phone>93-723-1010</phone>
      <phone_ext>21490</phone_ext>
      <email>apallill@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Xavier Serra-Aracil, MD,PhD</last_name>
      <phone>93-723-1010</phone>
      <phone_ext>21490</phone_ext>
      <email>xserraa@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Anna Pallisera-Lloveras</investigator_full_name>
    <investigator_title>md, PhD</investigator_title>
  </responsible_party>
  <keyword>Rectal cancer</keyword>
  <keyword>Sexual dysfunction</keyword>
  <keyword>Urinary dysfunction</keyword>
  <keyword>Rectal nerves damage</keyword>
  <keyword>Total Mesorectal Excision</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

